MedTrace Logo

Predictors of Response to Iron and Erythropoietin Stimulating Agents

NCT03658876 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 197

Last updated 2019-07-05

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to identify predictors of treatment response. This involves collected baseline clinical parameters and bloods for biochemical parameters prior to administering the study treatment. A positive outcome following treatment was defined as an uptitration of haemoglobin by greater than 5g/l within 2 months. The study evaluated the participants response to treatment against the clinical and biochemical information collected prior to treatment being received.

Conditions

  • Renal Failure Chronic
  • Anemia

Interventions

DRUG

Iron Sucrose Solution for Injection

200mg iron sucrose given on 5 successive haemodialysis sessions

DRUG

Epoetin Beta

Uptitration of epoetin beta dose. Scale as follows (in units /session): 0-1000-2000-3000-4000-6000-8000-12000

Sponsors & Collaborators

  • Imperial College London

    lead OTHER

Principal Investigators

  • Damien Ashby, MBBS · Imperial College Healthcare NHS Trust

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-03
Primary Completion
2016-12-31
Completion
2017-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03658876 on ClinicalTrials.gov